JP2014508759A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014508759A5 JP2014508759A5 JP2013554892A JP2013554892A JP2014508759A5 JP 2014508759 A5 JP2014508759 A5 JP 2014508759A5 JP 2013554892 A JP2013554892 A JP 2013554892A JP 2013554892 A JP2013554892 A JP 2013554892A JP 2014508759 A5 JP2014508759 A5 JP 2014508759A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- composition
- galactosyltransferase
- domain
- sialyltransferase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305200.5 | 2011-02-24 | ||
| EP11305200 | 2011-02-24 | ||
| EP11306090 | 2011-09-01 | ||
| EP11306090.9 | 2011-09-01 | ||
| PCT/EP2012/053065 WO2012113863A1 (en) | 2011-02-24 | 2012-02-23 | Method of production of sialylated antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014508759A JP2014508759A (ja) | 2014-04-10 |
| JP2014508759A5 true JP2014508759A5 (https=) | 2015-02-19 |
Family
ID=45774189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013554892A Pending JP2014508759A (ja) | 2011-02-24 | 2012-02-23 | シアリル化抗体の生産の方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140046032A1 (https=) |
| EP (1) | EP2678357A1 (https=) |
| JP (1) | JP2014508759A (https=) |
| AR (1) | AR085302A1 (https=) |
| TW (1) | TW201241182A (https=) |
| WO (1) | WO2012113863A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| UY34317A (es) | 2011-09-12 | 2013-02-28 | Genzyme Corp | Anticuerpo antireceptor de célula T (alfa)/ß |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| EP2877589B1 (en) | 2012-07-26 | 2024-03-06 | Momenta Pharmaceuticals, Inc. | Glycoproteins with anti-inflammatory properties |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| US9790268B2 (en) | 2012-09-12 | 2017-10-17 | Genzyme Corporation | Fc containing polypeptides with altered glycosylation and reduced effector function |
| US9701753B2 (en) | 2013-03-11 | 2017-07-11 | Genzyme Corporation | Hyperglycosylated binding polypeptides |
| HK1207960A1 (en) | 2013-03-12 | 2016-02-19 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US10450361B2 (en) | 2013-03-15 | 2019-10-22 | Momenta Pharmaceuticals, Inc. | Methods related to CTLA4-Fc fusion proteins |
| ES2802274T3 (es) * | 2013-05-02 | 2021-01-18 | Momenta Pharmaceuticals Inc | Glicoproteínas sialiladas |
| WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
| CA2908407C (en) | 2013-05-29 | 2022-06-14 | F. Hoffmann-La Roche Ag | Quantitative control of sialylation |
| EP3017057B1 (en) | 2013-07-05 | 2019-10-02 | F.Hoffmann-La Roche Ag | Process for the mono- and bi-sialylation of glycoproteins employing n-terminally truncated beta-galactoside alpha-2,6-sialyltransferase mutants |
| EP2824176A1 (en) | 2013-07-11 | 2015-01-14 | Siamed'xpress | Methods for producing sialylated therapeutic proteins |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| WO2015057622A1 (en) * | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| WO2015143091A1 (en) | 2014-03-19 | 2015-09-24 | Genzyme Corporation | Site-specific glycoengineering of targeting moieties |
| SG11201700446XA (en) | 2014-07-21 | 2017-02-27 | Glykos Finland Oy | Production of glycoproteins with mammalian-like n-glycans in filamentous fungi |
| EP3037527A1 (en) * | 2014-12-22 | 2016-06-29 | F. Hoffmann-La Roche AG | Sialyltransferase without CMP-dependent sialidase activity |
| WO2016102436A1 (en) | 2014-12-22 | 2016-06-30 | F. Hoffmann-La Roche Ag | Cmp-dependent sialidase activity |
| JP7516047B2 (ja) | 2016-11-23 | 2024-07-16 | アセチロン ファーマシューティカルズ インコーポレイテッド | ヒストン脱アセチル化酵素阻害剤とｃｄ３８阻害剤とを含む医薬組み合わせ物及びその使用方法 |
| EP3354278A1 (en) * | 2017-01-31 | 2018-08-01 | Sanofi | Neuronal cell protective effect of antibodies specific for the protofibrillar form of the beta-amyloid peptide |
| FR3080376B1 (fr) * | 2018-04-20 | 2022-12-09 | Lab Francais Du Fractionnement | Autoanticorps hautement sialyles et leurs utilisations |
| CN120192414A (zh) | 2019-04-03 | 2025-06-24 | 建新公司 | 具有降低的断裂的抗αβTCR结合多肽 |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| EP4430174A1 (en) * | 2021-11-09 | 2024-09-18 | Amgen Inc. | Production of therapeutic proteins |
| WO2025101901A1 (en) * | 2023-11-10 | 2025-05-15 | The Board Of Trustees Of The Leland Stanford Junior University | Use of sialylated ivig or igg fc region-containing protein for preventing or treating respiratory virus diseases |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US5474896A (en) | 1992-05-05 | 1995-12-12 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5830729A (en) | 1996-04-18 | 1998-11-03 | Institut Pasteur | I Sce I-induced gene replacement and gene conversion in embryonic stem cells |
| US20020045207A1 (en) * | 1997-10-31 | 2002-04-18 | Lynne A. Krummen | Glycoprotein production process |
| US6761888B1 (en) | 2000-05-26 | 2004-07-13 | Neuralab Limited | Passive immunization treatment of Alzheimer's disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2414772C (en) | 2000-07-07 | 2011-06-28 | Jan Naslund | Prevention and treatment of alzheimer's disease |
| DE60236182D1 (de) | 2001-09-14 | 2010-06-10 | Cellectis | Zufällige integration von polynukleotide nach in vivo linearisierung |
| EP3202899B1 (en) | 2003-01-28 | 2020-10-21 | Cellectis | Custom-made meganuclease and use thereof |
| PT1896071E (pt) * | 2005-06-30 | 2015-07-09 | Janssen Biotech Inc | Métodos e composições com melhorias na atividade terapêutica |
| SI1945665T1 (sl) | 2005-10-21 | 2012-03-30 | Genzyme Corp | Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo |
| US20080206246A1 (en) * | 2006-04-05 | 2008-08-28 | Ravetch Jeffrey V | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| EP1959996A2 (en) | 2005-12-12 | 2008-08-27 | AC Immune S.A. | Monoclonal antibody |
| CA2647524C (en) | 2006-04-05 | 2019-11-26 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| AU2007317755A1 (en) | 2006-10-27 | 2008-05-15 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| JP2010512306A (ja) * | 2006-10-27 | 2010-04-22 | ザ ロックフェラー ユニバーシティー | 抗炎症特性が増強され、細胞毒性特性が減少したポリペプチドおよび関連する方法 |
| AR063975A1 (es) * | 2006-11-28 | 2009-03-04 | Centelion | Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada |
| MX338397B (es) | 2007-08-29 | 2016-04-15 | Sanofi Aventis | Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso. |
| BRPI0818623A2 (pt) | 2007-10-05 | 2017-05-23 | Ac Immune Sa | composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal |
| US20100074901A1 (en) | 2007-10-15 | 2010-03-25 | Marc Hubert Mercken | Human anti-amyloid antibodies, compositions, methods and uses |
| US8586706B2 (en) | 2007-10-25 | 2013-11-19 | Kagoshima University | Peptide vaccine using mimic molecules of amyloid β peptide |
| EP2205752B1 (en) | 2007-10-25 | 2016-08-10 | Sangamo BioSciences, Inc. | Methods and compositions for targeted integration |
| EP2224000B1 (en) | 2007-10-29 | 2020-05-13 | TAO Health Life Pharma Co., Ltd. | Antibody and use thereof |
| EP2207568B1 (en) | 2007-11-16 | 2017-05-31 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| US8921523B2 (en) | 2007-12-11 | 2014-12-30 | Glaxo Group Limited | Humanized anti-beta-amyloid antibodies |
| EP2233502A1 (en) | 2009-03-27 | 2010-09-29 | Deutsches Rheuma-Forschungszentrum Berlin | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them |
| FR2945538B1 (fr) * | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| US10087236B2 (en) * | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
-
2012
- 2012-02-22 AR ARP120100573A patent/AR085302A1/es unknown
- 2012-02-23 EP EP12706541.5A patent/EP2678357A1/en not_active Withdrawn
- 2012-02-23 TW TW101106076A patent/TW201241182A/zh unknown
- 2012-02-23 JP JP2013554892A patent/JP2014508759A/ja active Pending
- 2012-02-23 WO PCT/EP2012/053065 patent/WO2012113863A1/en not_active Ceased
- 2012-02-23 US US14/000,035 patent/US20140046032A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014508759A5 (https=) | ||
| Gunn et al. | A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus | |
| JP2021184741A (ja) | カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用 | |
| TW200925273A (en) | Antibody constant region mutant | |
| TW201241182A (en) | Method of production of sialylated antibodies | |
| JP2010538608A5 (https=) | ||
| JP2018085988A5 (https=) | ||
| TWI780097B (zh) | 於活體外進行抗體之糖基化工程 | |
| TWI820484B (zh) | 抗hla-dq2.5抗體及其用於治療乳糜瀉的用途 | |
| JP2016511277A5 (https=) | ||
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| HRP20192052T1 (hr) | Protutijela anti-siglec-8 te njihovi postupci i uporabe | |
| KR20140108520A (ko) | CD1d에 대한 항체 | |
| TWI781973B (zh) | 用於以活體外進行抗體糖基化工程之方法 | |
| WO2010109010A1 (en) | Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them | |
| US20230073926A1 (en) | Highly sialylated multimeric binding molecules | |
| EP4017533A1 (en) | Igm glycovariants | |
| CN105531289A (zh) | 抗cd83抗体及其用途 | |
| PE20191662A1 (es) | Anticuerpos anti-il-5 | |
| EP3108004A1 (en) | Methods to produce single glycoform antibodies | |
| CN118475614A (zh) | 具有增强的效应子功能的生物合成双互补位或双特异性结合分子 | |
| CA3235999A1 (en) | Biosynthetic monovalent binding molecules with enhanced effector functions | |
| AU2021385606B2 (en) | Antibody for enrichment of cells | |
| TW202333781A (zh) | 抗ｈｌａ－ｄｑ２﹒５抗體製劑 | |
| TW202003555A (zh) | 用於純化重組多肽之方法 |